Blackstone, Intellia, Cellex to launch company addressing limitations of cell therapies

By Samantha Black, PhD, The Science Advisory Board editor in chief

June 22, 2021 -- Blackstone Life Sciences has committed $250 million toward the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company. Also taking part in the launch are Intellia Therapeutics and Cellex Cell Professionals, the parent company of GEMoaB, a clinical-stage cell therapy company.

The new company will combine Intellia's differentiated allogeneic cell platform and CRISPR cell engineering with GEMoaB's clinical-stage universal CAR T platforms. It will be headquartered in Cambridge, MA, and will acquire Cellex's subsidiary GEMoaB with established offices and labs in Dresden, Germany.

Andrew Schiermeier, PhD, current executive vice president and chief operating officer of Intellia, will lead the launch as president and CEO.

The newly formed company will receive an exclusive license to combine Intellia's CRISPR-Cas9 allogeneic platform with GEMoaB's switchable, universal CAR T-cell platforms, UniCAR and RevCAR. Also, GEMoaB will become a subsidiary of the new company and will continue to advance its clinical stage CAR T-cell programs independently. Under the transaction, the new company and Intellia will gain access to Cellex's established cell therapy manufacturing capabilities to accelerate their respective ex vivo programs.

Simultaneously, Intellia and the new company will enter into a codevelopment and cofunding agreement to develop an allogeneic universal CAR T-cell product for an immuno-oncology indication. Intellia will have an additional option to enter a second similar agreement from selected allogeneic universal CAR T-cell therapy products developed under the collaboration.

"As the sole founding investor, Blackstone will be actively involved in building this platform, leveraging our deep expertise in oncology and our scale capital," said Nicholas Galakatos, PhD, global head of Blackstone Life Sciences.

Blackstone Life Sciences, Intellia, and Cellex will each have equal ownership of the new company. The transaction is expected to close in the third quarter of 2021.

Potential of gene editing for clinical use highlighted at ASGCT 2021
From base editing to in vivo CRISPR therapeutics and CRISPR-modified bacteriophages, scientists discussed innovations in preclinical research that have...
Intellia demonstrates efficacy of gene therapy in preclinical models
Intellia Therapeutics has demonstrated that physiological protein levels of human alpha-1 antitrypsin in nonhuman primates can be achieved following a...
Intellia to advance CRISPR treatment for sickle cell
Intellia Therapeutics has received a grant from the Bill & Melinda Gates Foundation to research in vivo sickle cell disease treatments using its CRISPR/Cas9...

Copyright © 2021

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter